News & Videos - PTC THERAPEUTICS INC.

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results PR Newswire SOUTH PLAINFIELD, N.J., April 11, 2024 SOUTH PLAINFIELD, N.J. , April 11, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25 , at 4:30 p.m. ET . To access the call by phone, please click...

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PR Newswire SOUTH PLAINFIELD, N.J., March 28, 2024 - First marketing authorization submission for sepiapterin with additional global submissions to follow in 2024 - SOUTH PLAINFIELD, N.J. , March 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin MAA to the European Medicines Agency. The MAA submission is for the treatment of pediatric and adult patients with PKU,...

PTC Therapeutics proporciona actualizaciones reglamentarias clave PR Newswire SOUTH PLAINFIELD, Nueva Jersey, 19 de marzo de 2024 - BLA presentado a la FDA para Upstaza™ para el tratamiento de la deficiencia de AADC - - A mediados de año se presentará un nuevo NDA para Translarna™ en función de los comentarios de la FDA - SOUTH PLAINFIELD, Nueva Jersey , 19 de marzo de 2024 /PRNewswire/ -- PTC Therapeutics, Inc. ha anunciado hoy la presentación de una BLA a la FDA estadounidense para...

PTC Therapeutics Provides Key Regulatory Updates PR Newswire SOUTH PLAINFIELD, N.J., March 19, 2024 - BLA submitted to FDA for Upstaza™ for the treatment of AADC deficiency - - NDA to be submitted mid-year for Translarna™ based on FDA feedback - SOUTH PLAINFIELD, N.J. , March 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of aromatic L-amino acid...

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J., Feb. 29, 2024 – 34% year-over-year growth in 2023 total revenue – – Global filings of sepiapterin remain on track with first submission of the EU MAA expected in March – – Potential NDA submission for vatiquinone for Friedreich ataxia expected in late 2024 – SOUTH PLAINFIELD, N.J. , Feb. 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc.,...

PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SOUTH PLAINFIELD, N.J., Feb. 27, 2024 SOUTH PLAINFIELD, N.J. , Feb. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: TD Cowen 44th Annual Health Care Conference Monday, March 4 , at 1:30 p.m. EST Leerink Partners Global Biopharma Conference 2024 Monday, March 11 , at 2:40 p.m. EDT Barclays 26th Annual Healthcare...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J., Feb. 22, 2024 SOUTH PLAINFIELD, N.J. , Feb. 22, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Feb. 15, 2024 , the company approved non-statutory stock options to purchase an aggregate of 1,840 shares of its common stock and 4,275 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting,...

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J., Feb. 15, 2024 SOUTH PLAINFIELD, N.J. , Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29 , at 4:30 p.m. EST . To access the...

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure PR Newswire SOUTH PLAINFIELD, N.J., Jan. 25, 2024 SOUTH PLAINFIELD, N.J. , Jan. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion following the re-examination procedure for the conditional marketing...

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J., Jan. 8, 2024 – Unaudited 2023 total revenue of $ 946 million, representing 35% year-over-year growth – – Regulatory filings in the EU and US for sepiapterin in PKU, a potential $1 billion global commercial opportunity, remain on track for 2024 – – Multiple study readouts planned for 2024, including 12-month interim data from...

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J., Jan. 3, 2024 SOUTH PLAINFIELD, N.J. , Jan. 3, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, Jan. 8 , at 7:30 a.m. PST / 10:30 a.m. EST . The presentations will be webcast live on the Events and Presentations page under the Investor section...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J., Dec. 14, 2023 SOUTH PLAINFIELD, N.J. , Dec. 14, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 10, 2023 , the company approved non-statutory stock options to purchase an aggregate of 3,575 shares of its common stock and 3,035 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting,...

PTC Therapeutics ofrece novedades sobre las actividades regulatorias de Translarna™ PR Newswire SOUTH PLAINFIELD, Nueva Jersey, 5 de diciembre de 2023 SOUTH PLAINFIELD , Nueva Jersey , 5 de diciembre de 2023 /PRNewswire/ -- PTC Therapeutics, Inc. anunció hoy novedades sobre las actividades regulatorias de Translarna™ (ataluren) en Europa y los Estados Unidos. Según lo previsto, PTC presentó el documento informativo como parte de la reevaluación de la opinión negativa inicial del Comité...

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities PR Newswire SOUTH PLAINFIELD, N.J., Dec. 5, 2023 SOUTH PLAINFIELD, N.J. , Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States . As planned, PTC has submitted the briefing document as part of the re-examination of the initial Committee for Medicinal Products for Human Use (CHMP) negative opinion on the...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J., Nov. 3, 2023 SOUTH PLAINFIELD, N.J. , Nov. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023 , the company approved non-statutory stock options to purchase an aggregate of 14,005 shares of its common stock and 19,125 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to...

PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results PR Newswire SOUTH PLAINFIELD, N.J., Oct. 26, 2023 – Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position following recent restructuring initiatives and Royalty Pharma transaction – – PTC provides regulatory updates for pipeline programs – SOUTH PLAINFIELD, N.J. , Oct. 26, 2023 /PRNewswire/ -- PTC Therapeutics,...

PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion PR Newswire SOUTH PLAINFIELD, N.J., Oct. 19, 2023 - PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M - - Financing proceeds will be used to retire Blackstone debt obligations and fund planned operations - SOUTH PLAINFIELD, N.J. , Oct. 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an agreement with...

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PR Newswire SOUTH PLAINFIELD, N.J., Oct. 16, 2023 SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26 , at 4:30 p.m. ET . To access the call by phone, please click here...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire NEW YORK, Sept. 29, 2023 NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc . ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether PTC and certain of its officers...

PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce PR Newswire SOUTH PLAINFIELD, N.J., Sept. 28, 2023 - Translarna CHMP opinion re-examination request to be submitted - SOUTH PLAINFIELD, N.J. , Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio prioritization continues the process initiated in May 2023 as the company continues to focus its...